History of interstitial lung disease.
History of interstitial lung disease or pneumonitis requiring supplemental oxygen or treatment with oral or intravenously administered corticosteroids
Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis
Patients with interstitial lung disease and/or pneumonitis are not eligible
No known interstitial fibrosis or interstitial lung disease
Patients must not have symptomatic interstitial lung disease or pneumonitis
Patients must not have known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
Patients must not have a history of pneumonitis or interstitial lung disease
Patients must not have evidence of interstitial lung disease or pneumonitis
No patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
Participants may not have clinically active or symptomatic interstitial lung disease or interstitial pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention), or a history of clinically significant interstitial lung disease or radiation pneumonitis
Subjects with a history of interstitial lung disease and/or pneumonitis
Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis.
Evidence of interstitial lung disease or active, non-infectious pneumonitis
History of interstitial lung disease or chronic pneumonitis
History of interstitial lung disease
Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis.
Interstitial lung disease or pneumonitis that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity; patients with prior pneumonitis that has resolved are eligible (for treatment phase)
Has a history of interstitial lung disease.
History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis)
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Participants with current pneumonitis or interstitial lung disease
Interstitial lung disease or history of pneumonitis requiring treatment with corticosteroids
Patients with previous history or active interstitial lung disease or pulmonary fibrosis, or a history of other clinically significant lung diseases
History of pneumonitis or other interstitial lung disease
Subjects with interstitial lung disease or interstitial pneumonitis that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis.
History of interstitial lung disease or non-infectious pneumonia.
History of interstitial lung disease
Has active pneumonitis requiring treatment with steroids or active interstitial lung disease
Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis. Patients with a history of prior radiation pneumonitis are not excluded.
History of or active pneumonitis or interstitial lung disease:\r\n* For history of pneumonitis to be an exclusion, patient had to have required supplemental oxygen or corticosteroid treatment; radiographic changes alone are not an exclusion
The subject has any history or evidence of active, non-infectious pneumonitis or interstitial lung disease
Known history or confirmation of active pneumonia, pneumonitis, symptomatic interstitial lung disease, or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen therapy.
Patients with history of interstitial lung disease or pneumonitis.
Patients with history of interstitial lung disease.
Patient has a known history of chronic interstitial lung disease
SAFETY RUN-IN: Has evidence of interstitial lung disease or active, non-infectious pneumonitis
RANDOMIZED PHASE II CLINICAL TRIAL: Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Has history of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of pneumonitis or interstitial lung disease.
History of interstitial lung disease or pneumonitis.
Has a history of interstitial lung disease related to prior EGFR inhibitor therapy.
History of interstitial lung disease or pneumonitis
History of interstitial lung disease or pneumonitis
Known pre-existing interstitial lung disease
Patients with blood oxygen saturation < 90% at rest; patients must not have symptomatic interstitial lung disease, pneumonitis, or known pulmonary fibrosis
Has a history of interstitial lung disease
Participants with a history of interstitial lung disease (ILD) / pneumonitis
Has a history of (non-infectious) pneumonitis /interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease that requires steroids.
Participants with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity in the opinion of the treating investigator
History of interstitial lung disease.
Has a history of interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
History of interstitial lung disease or pneumonitis
Has interstitial lung disease that has required oral or intravenous glucocorticoids to assist with management.
Known non-infectious pneumonitis or any history of interstitial lung disease
Currently active pneumonitis or interstitial lung disease.
Subjects with a history of interstitial lung disease
Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis.
History of interstitial lung disease, pneumonitis or other clinically significant lung diseases.
Patients with any evidence of current interstitial lung disease (ILD) or pneumonitis
Evidence of interstitial lung disease or noninfectious pneumonitis.
History of interstitial lung disease or pneumonitis that has required steroid administration
History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease
Has a history of interstitial lung disease
Subjects with a history of interstitial lung disease
History of adrenal insufficiency, pneumonitis, interstitial lung disease, or inflammatory bowel disease
The participant has any history or evidence of active, non-infectious pneumonitis or interstitial lung disease
History of interstitial pneumonitis
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
History of interstitial lung disease
Patients with evidence of interstitial lung disease (bilateral, diffuse, parenchymal lung disease)
Subjects with a history of interstitial lung disease; patients requiring continuous supplemental oxygen are excluded to avoid possible complications from pneumonitis
History of pneumonitis or interstitial lung disease
Clinically significant interstitial lung disease
History or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary function
Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management.
Patient has interstitial lung disease
Symptomatic interstitial lung disease
Evidence of interstitial lung disease
Known pre-existing interstitial lung disease
Persistent proteinuria ? grade 3 Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Known pre-existing interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Evidence of interstitial lung disease or active, non-infectious pneumonitis
Current or history of interstitial pneumonitis,
Pre-existing interstitial lung disease
History of interstitial lung disease and/or pneumonitis
History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
History of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis
Patients with active interstitial lung disease and non-infectious pneumonitis or a history of active interstitial lung disease or pneumonitis requiring treatment with steroids or that may interfere with the detection or management of suspected drug-related pulmonary toxicity. Patients with lung cancer with a remote history of pneumonitis following chemo-radiation treatment that has resolved are allowed.\r\n* Note: Patients with chronic obstructive pulmonary disease (COPD) whose disease is controlled (per investigator judgment) at trial entry are not excluded.
Interstitial lung disease that is symptomatic or which may interfere with the detection or management of suspected drug-related pulmonary toxicity.
Subjects with active interstitial pneumonitis.
EXCLUSION - DURVALUMAB DRUG-SPECIFIC: Participant has evidence of interstitial lung disease or active non-infectious pneumonitis.
Has evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring oral or intravenous glucocorticoids
Known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis
Has a known history of interstitial lung disease
History or any evidence of interstitial lung disease;
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention). (Note, this does NOT include immune-mediated pneumonitis)
Evidence of interstitial lung disease or active, non-infectious pneumonitis
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Participants must not have evidence of interstitial lung disease
History of pneumonitis or interstitial lung disease (ILD).
Has known history of, or any evidence of active, interstitial lung disease or non-infectious pneumonitis requiring corticosteroid therapy
Active interstitial lung disease (ILD)/pneumonitis or a prior history of ILD/pneumonitis requiring treatment with steroids.
Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
Known pre-existing interstitial or inflammatory lung disease.
Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Patients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis/pneumonia or pulmonary pathology that is not well controlled in the opinion of the treating physician and/or principal investigator (PI).
Presence of cavitation of central pulmonary lesion, or radiographic evidence of pneumonitis or other extensive bilateral lung disease such as interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease
Patients with evidence of interstitial lung disease or active, non-infectious pneumonitis; patients with a history of interstitial lung disease or non-infectious pneumonitis requiring treatment with steroids are also excluded
Patients with evidence of non-infectious pneumonitis or history of interstitial lung disease
History or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary function
Evidence of interstitial lung disease
History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.
Evidence of active interstitial lung disease or active non-infectious pneumonitis
Participants with clinically active or symptomatic interstitial lung disease or interstitial pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention) and patients with history of clinically significant interstitial lung disease or radiation pneumonitis
History of medically diagnosed pneumonitis or interstitial lung disease
History of interstitial lung disease or pneumonitis.
Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring oral or IV glucocorticoids
Has a known history of, or any evidence of, interstitial lung disease or active non- infectious pneumonitis
A history of pneumonitis or extensive bilateral lung disease of non-malignant etiology.
Subjects with a history of interstitial lung disease.
Has any history of interstitial lung disease (pulmonary fibrosis or severe radiation pneumonitis) or is suspected to have such disease by imaging during screening.
Has a history of interstitial lung disease
History of interstitial lung disease or pneumonitis
Has evidence of interstitial lung disease
Has evidence of interstitial lung disease
History of pneumonitis or drug-related inflammatory lung disease
Patients with a history of interstitial lung disease or pneumonitis
History of extensive, disseminated, bilateral or presence of grade 3 or 4 interstitial fibrosis or interstitial lung disease including pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis or pulmonary fibrosis; patients with history of prior radiation pneumonitis are not excluded
History of pneumonitis or interstitial lung disease
Has a history of interstitial lung disease.
History or active interstitial lung disease
Known interstitial lung disease
Patient with active interstitial lung disease (ILD)/pneumonitis or a prior history of ILD/pneumonitis requiring treatment with steroids
Have evidence of interstitial lung disease or active, non-infectious pneumonitis
Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
History or clinically confirmed pneumonitis or interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of interstitial lung disease or pneumonitis
History or the presence of pulmonary interstitial disease, or drug-related pneumonitis
History of symptomatic idiopathic pulmonary fibrosis or interstitial lung disease
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)
Active or prior documented history of pneumonitis or interstitial lung disease
History of interstitial lung disease or pneumonitis
Patient has a known history of chronic interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Evidence of interstitial lung disease or active, non-infectious pneumonitis
GROUP 5:\r\n* Limited cutaneous scleroderma and SSc-related pulmonary disease with FVC < 80% or hemoglobin-adjusted DLCO < 70% of predicted\r\n* AND evidence of alveolitis/interstitial lung disease by high-resolution chest CT scan and/or by BAL (interstitial lung disease may be nonspecific interstitial pneumonia [NSIP] or usual interstitial pneumonia [UIP]; A bronchoalveolar lavage [BAL] should be done to confirm the findings of alveolitis only if the high resolution CT scan [HRCT] fails to show findings typically associated with systemic sclerosis changes [ground glass, NSIP, UIP, SSc related interstitial lung disease])\r\n* Alveolitis by BAL cell count will be defined based on a BAL cell differential count (> 3% neutrophils and/or > 2% eosinophils) from any lavaged lobe
Interstitial lung disease
Interstitial lung disease that is symptomatic or which may interfere with the detection or management of suspected drug-related pulmonary toxicity
Has a history of interstitial lung disease or pneumonitis from any cause
Known pre-existing interstitial lung disease
Evidence of interstitial lung disease
Known history or evidence of interstitial lung disease or active, non-infectious pneumonitis
Patients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis/pneumonia or pulmonary pathology that is not well controlled in the opinion of the treating physician and/or principal investigator (PI)
History and/or confirmed interstitial lung disease (ILD)/pneumonitis, extensive bilateral lung disease on high-resolution computed tomography (HRCT) scan
Interstitial lung disease
Has evidence of interstitial lung disease
Clinically significant interstitial pulmonary disease or known diagnosis of interstitial lung disease (ILD)
Evidence of interstitial lung disease
History of, or evidence of clinically active, interstitial lung disease
History of interstitial lung disease or pneumonitis
Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management; lymphangitic spread of the NSCLC is not exclusionary
History of extensive interstitial lung disease, e.g., pneumonitis or pulmonary fibrosis or any evidence of extensive interstitial lung disease on baseline chest computed tomography (CT) scan
Patients have history of diagnosed interstitial lung disease
History of pneumonitis or interstitial lung disease
Has evidence or a history of interstitial lung disease
Patients with a history of pneumonitis or interstitial lung disease
Patients with history of interstitial lung disease or active, non-infectious pneumonitis are not eligible\r\n* NOTE: history of radiation pneumonitis in the radiation field (fibrosis) is permitted
Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis.
Significant pulmonary disease, including pulmonary hypertension, interstitial lung disease, or active, non-infectious pneumonitis
Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
Has known history of/active pneumonitis requiring treatment with steroids or history of/active interstitial lung disease
Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis.
Known prior history of interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e. affecting activities of daily living or requiring therapeutic intervention)
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Has evidence of interstitial lung disease
Has a history of interstitial lung disease or pneumonitis.
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Patients with interstitial lung disease.
Evidence of interstitial lung disease or active, non-infectious pneumonitis
Has evidence of interstitial lung disease
History or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary function
History or concurrent condition of interstitial lung disease and/or severely impaired lung function (as judged by the investigator)
Has evidence of interstitial lung disease
History of interstitial lung disease or pneumonitis
Symptomatic lung disease
History of interstitial lung disease/pneumonitis
CERITINIB EXCLUSION CRITERIA: Known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis
REGORAFENIB EXCLUSION CRITERIA: Known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis
ENTRECTINIB EXCLUSION CRITERIA: Known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis
History of pneumonitis or active lung infection
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)
Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of interstitial lung disease
Past history of interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
Evidence of interstitial lung disease or active non-infectious pneumonitis
History of interstitial lung disease or pneumonitis
Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nPatients with prior history of pneumonitis and/or interstitial lung disease will be excluded
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Subject has evidence of interstitial lung disease or active, non-infectious pneumonitis
History of interstitial lung disease or pneumonitis
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Patients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis that is uncontrolled in the opinion of the treating physician
Interstitial lung disease or pneumonitis
History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function
Has evidence of interstitial lung disease or active, non-infectious pneumonitis that required oral or intravenous glucocorticoids to assist with management; lymphangitic spread of the non-small cell lung cancer (NSCLC) is not exclusionary
Has evidence of interstitial lung disease
Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity Prior therapy:
Patients with known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis (i.e. affecting activities of daily living or requiring therapeutic intervention)
Evidence of pre-existing interstitial lung disease or active, non-infectious pneumonitis
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
History of interstitial lung disease or pneumonitis
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)
Subjects with a history of symptomatic interstitial lung disease
Patients with known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)
History of interstitial lung disease or pneumonitis
Patient has evidence of interstitial lung disease
History of interstitial lung disease or pneumonitis
Evidence of interstitial lung disease
History of interstitial lung disease or pneumonitis
No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
Patient has history of interstitial lung disease or known history of, or any evidence of active, noninfectious pneumonitis
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
Currently have or have a history of interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis that required steroid treatment.
Interstitial pneumonia or interstitial fibrosis of the lung, which in the opinion of the site investigator could compromise the subject or the study
History of treatment-related interstitial lung disease/pneumonitis
History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis, or any evidence of interstitial lung disease on baseline chest CT scan\r\n* For the NSCLC expanded cohort only: scarring from previous radiation therapy or pneumonia allowed
Evidence of interstitial lung disease or active pneumonitis
History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator).
Known history of, or any evidence of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis diagnosed based on imaging or clinical findings, or uncontrolled systemic diseases, including diabetes, hypertension, acute lung diseases, etc
History of interstitial lung disease or non-infectious pneumonitis, unless induced by radiation therapy
Evidence of interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis
History of interstitial lung disease and/or immune mediated pneumonitis
Interstitial lung disease or pulmonary fibrosis
Known history of active pneumonia, pneumonitis, symptomatic interstitial lung disease, or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen therapy.
Has a medical history of clinically significant lung diseases (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period
Has a history of interstitial lung disease.
History of interstitial lung disease or pneumonitis
Interstitial lung disease
Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
Has evidence of interstitial lung disease, active, non-infectious pneumonitis
Patients with known history of interstitial lung disease or idiopathic pneumonitis
Active or prior documented interstitial lung disease
History of interstitial lung disease or pneumonitis
History of interstitial lung disease (ILD)/pneumonitis requiring treatment with steroids and patients with active ILD/pneumonitis
Evidence of interstitial lung disease
History of interstitial lung disease or pneumonitis
Evidence of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of or active, non-infectious pneumonitis and/or a history of interstitial lung disease
Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
TREATMENT: Patients with current or a history of interstitial lung disease, known severely impaired lung function (spirometry and carbon monoxide diffusing capability test (DLCO) 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air) or non-infectious pneumonitis will not be assigned treatment with everolimus or trametinib DMSO; symptoms should have resolved and course of antibiotics been completed for patients with a history of infectious pneumonitis to be eligible
Subjects with any history of interstitial lung disease or a history of > or = to grade 2 radiation pneumonitis
DOSE ESCALATION COHORT: Evidence of or any history of interstitial lung disease or active, noninfectious pneumonitis including symptomatic and/or pneumonitis requiring treatment
DOSE EXPANSION COHORT: Evidence of or any history of interstitial lung disease or active, noninfectious pneumonitis including symptomatic and/or pneumonitis requiring treatment
Patients with evidence of interstitial lung disease or active, non-infectious pneumonitis
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
Patients with known and confirmed diagnosis of interstitial lung disease (IDL)
Interstitial lung disease or pneumonitis not secondary to ECD
Evidence of interstitial lung disease
Known pre-existing interstitial lung disease
History of interstitial lung disease or pneumonitis
History of interstitial lung disease or pneumonitis
History of interstitial lung disease or pneumonitis
Patients with a history of interstitial lung disease or pneumonitis
Patients with clinically significant interstitial lung disease or history of cardiac disease
Patient must not have a history of interstitial lung disease or pneumonitis
Patients with known interstitial fibrosis or interstitial lung disease are not eligible
Patients with active interstitial lung disease
Patients must not have any known clinically active interstitial lung disease
Known history of, or any evidence of interstitial lung disease or active, non-infectious pneumonitis
Patients must not have interstitial lung disease that is symptomatic or disease that may interfere with the detection or management of suspected drug-related pulmonary toxicity
Patients with known interstitial fibrosis or interstitial lung disease.
Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
Evidence of clinically active interstitial lung disease (ILD) and/or history of ILD
Evidence of interstitial lung disease or active, noninfectious pneumonitis
History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.
Symptomatic intrinsic lung disease or lung involvement
CLINICAL/LABORATORY CRITERIA: Patient must not have prior history of interstitial lung disease or pneumonitis
Clinically significant lung disease including known history or evidence of interstitial lung disease or chronic obstructive pulmonary disease (COPD) that requires oxygen therapy
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease
History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan
History or evidence of active, non-infectious pneumonitis or interstitial lung disease
History of interstitial lung disease
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
Patients with a history of interstitial lung disease or pneumonitis
Subject has a history of pneumonitis or interstitial lung disease. Hepatocellular Carcinoma Exclusion Criterion:
Has interstitial lung disease or a history of pneumonitis that required oral of IV glucocorticoids to assist with management.
Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis.
Evidence of active non-infectious pneumonitis/interstitial lung disease
History of interstitial lung disease
Subject has interstitial lung disease or a history of pneumonitis
No symptomatic pulmonary fibrosis or interstitial pneumonitis >= grade 2
Has a history of interstitial lung disease.
History of symptomatic or p previously established interstitial lung disease
Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.
Symptomatic interstitial lung disease or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen.
SUB-PROTOCOL AIM A: Patients with a history of interstitial lung disease and/or pneumonia
Interstitial lung disease (subjects with existing pneumonitis as a result of radiation are not excluded, however, subjects cannot be oxygen dependent).
Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung.
Interstitial lung disease or pneumonitis requiring oral or IV glucocorticoids
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Current or history of pneumonitis or interstitial lung disease
Has evidence or history of interstitial lung disease or active noninfectious pneumonitis
History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Has interstitial lung disease or active, non-infectious pneumonitis
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
Has history of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies..
Patients with a known history of severe interstitial lung disease or severe pneumonitis or active pneumonitis that is uncontrolled in the opinion of the treating physician
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Presence or history of interstitial lung disease or interstitial pneumonitis
History of interstitial lung disease, idiopathic pulmonary fibrosis, silicosis or connective tissue disorders
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
Patients must not have interstitial pneumonia or extensive symptomatic interstitial fibrosis of the lung
Interstitial lung disease or pneumonitis that has required oral or IV steroids
History of interstitial lung disease or unresolved pneumonitis
Known pre-existing interstitial lung disease.
History of or active interstitial lung disease
Has history of interstitial lung disease or pneumonitis.
Subjects with a history of interstitial lung disease
Interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment
Evidence of active noninfectious pneumonitis or history of interstitial lung disease.
History of or current drug-induced interstitial lung disease or pneumonitis grade ?2
History of interstitial lung disease
Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)
History of interstitial lung disease or unresolved pneumonitis
History of pneumonitis or interstitial lung disease, or any unresolved immune-related adverse events.
History of drug-induced interstitial lung disease (ILD), ILD, or radiation pneumonitis requiring treatment with steroid prior to study enrollment, or any evidence of clinically active ILD.
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Patients with active interstitial pneumonitis
Has known history of/active, non-infectious pneumonitis requiring treatment with steroids or has history of/active interstitial lung disease
Evidence of interstitial lung disease
Participant has history of interstitial lung disease (ILD) OR a history of pneumonitis that has required oral or IV steroids. Participants whose pneumonitis was solely as a result of radiation therapy for their NSCLC would not be excluded from the study unless they received oral/IV steroids to manage the pneumonitis.
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Past history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
History of interstitial lung disease, pneumonitis, autoimmune disease or syndrome that requires steroids or immunosuppressive agents.
Has evidence of interstitial lung disease, any active, non-infectious pneumonitis, or known active tuberculosis
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
History of pneumonitis or interstitial lung disease.
Subjects with a history of interstitial lung disease
Has evidence of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of or current interstitial lung disease
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Interstitial lung disease or history of pneumonitis requiring treatment with corticosteroids
Known pre-existing interstitial lung disease
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Evidence of interstitial lung disease or active non-infectious pneumonitis
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Has history of interstitial lung disease or active, non-infectious pneumonitis requiring steroids
Evidence of interstitial lung disease or active non-infectious pneumonitis
Patient with known pre-existing interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Have a history or the presence of pulmonary interstitial disease or drug-related pneumonitis.
Subjects with clinically significant interstitial lung disease, or obstructive disease without sufficient reserve
History of interstitial lung disease
Interstitial lung disease with ongoing signs and symptoms at the time of screening
Other clinically severe or uncontrolled systemic illness or any concurrent condition that in the view of the principal investigator could compromise the participant’s ability to tolerate vandetanib or could compromise study procedures or endpoints, including interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease
Any evidence of clinically active interstitial lung disease
History of interstitial lung disease or pneumonitis
Symptomatic interstitial lung disease or definitive evidence of interstitial lung disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at rest requiring current continuous oxygen therapy.
History of interstitial lung disease or pneumonitis
Presence of interstitial lung disease or pneumonitis
Patients with evidence of interstitial lung disease
Known pre-existing interstitial lung disease
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
Interstitial lung disease with ongoing signs and symptoms at the time of screening.
History of interstitial lung disease or pneumonitis
History of interstitial lung disease or pneumonitis
Subjects with a history of pneumonitis or interstitial lung disease
History or concurrent condition of interstitial lung disease
History or concurrent condition of interstitial lung disease or severely impaired pulmonary function
Known pre-existing interstitial lung disease.
Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
History of interstitial lung disease or pneumonitis
History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
Confirmed pneumonitis or interstitial lung disease
A history of clinically significant interstitial lung disease or pneumonitis
History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
Has a known history of interstitial lung disease
History and/or confirmed pneumonitis or interstitial lung disease
Has a history of interstitial lung disease
Known history of, or any evidence of, interstitial lung disease
Any evidence of clinically significant interstitial lung disease
Known interstitial lung disease
History of extensive interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any evidence of extensive interstitial lung disease on baseline chest computed tomography (CT) scan
Subject has history of drug-induced interstitial lung disease (ILD) or any evidence of active ILD.
Has a history of pneumonitis or idiopathic pulmonary fibrosis, or evidence of interstitial lung disease.
History of interstitial lung disease or pneumonitis
Presence of interstitial lung disease or history of pneumonitis requiring treatment with corticosteroids
Interstitial lung disease with ongoing signs and symptoms at the time of study registration.
History of extensive disseminated interstitial fibrosis or any grade of interstitial lung disease.
Known pre-existing interstitial lung disease
History of interstitial lung disease.
History of interstitial lung disease/pneumonitis from any cause
Subject has history of drug-induced interstitial lung disease (ILD) or any evidence of active ILD.
Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
Patients with interstitial lung disease or active, noninfectious pneumonitis
Have evidence of interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis
History of interstitial lung disease (ILD) eg, interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computed tomography (CT) or magnetic resonance imaging (MRI)
Subject has history of drug-induced interstitial lung disease or any evidence of active interstitial lung disease.
History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
Patients with a prior diagnosis of interstitial lung disease or pulmonary fibrosis
Pre-existing or current interstitial lung disease
History of interstitial pneumonitis
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of interstitial pneumonitis
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of interstitial lung disease (ILD)
History of interstitial pneumonitis and/or require supplemental oxygen therapy
History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
Known pre-existing Interstitial Lung Disease (ILD)
Patients with interstitial pneumonitis
History of interstitial lung disease or pneumonitis of any cause
Has a history of, active pneumonitis requiring treatment with steroids or history of/active interstitial lung disease
Patients with known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis (i.e. affecting activities of daily living or requiring therapeutic intervention)
Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
Has a history of interstitial lung disease.
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Patients with a history of interstitial
Non-malignant interstitial lung disease;
History of interstitial lung disease or active, non-infectious pneumonitis that required oral or intravenous corticosteroids
Known preexisting interstitial lung disease or pneumonitis
Known preexisting interstitial lung disease, interstitial pulmonary fibrosis, or connective tissue disorder associated lung disease
Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
Known pre-existing interstitial lung disease (ILD)
History of or known presence of extensive, disseminated/bilateral or Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, or pulmonary fibrosis, but not including a history of prior radiation pneumonitis. Patients with clinically significant lung disease requiring oxygen therapy (eg, COPD).
History of interstitial lung disease or pneumonitis.
History of interstitial lung disease (ILD)
History of interstitial lung disease or pneumonitis
History of interstitial lung disease (ILD)
Radiographically evident interstitial lung disease , concurrent infection, or a history of any of these conditions
Interstitial lung disease with ongoing signs and symptoms at the time of screening
Active pneumonitis or interstitial lung disease
History of interstitial lung disease or pneumonitis.
Interstitial lung disease with ongoing signs and symptoms at the time of registration
History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
Clinically significant lung disease (including pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, active infection/ history of opportunistic infections)
Known interstitial lung disease, drug-related pneumonitis, or radiation pneumonitis requiring steroid treatment
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
History of interstitial lung disease
Evidence of interstitial lung disease.
Any evidence of clinically active interstitial lung disease (patients with chronic,stable, radiographic changes who are asymptomatic need not be excluded).
Known or suspected history of interstitial lung disease.
History of interstitial lung disease
Subject has history of drug-induced interstitial lung disease (ILD) or any evidence of active ILD.
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
History of interstitial lung disease
Interstitial lung disease (subjects with existing pneumonitis as a result of radiation are not excluded, however, subjects must not be oxygen dependent).
Known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis.
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Any serious intercurrent or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol including but not limited to: \r\n* Uncontrolled diabetes mellitus (fasting plasma glucose > 130 mg/dL or 7.2 mmol/L)\r\n* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease\r\n* Active infections \r\n* Gastrointestinal disease limiting the ability to swallow oral medications or absorb oral medications including refractory nausea and vomiting, chronic gastrointestinal diseases, inflammatory bowel disease; malabsorption syndromes\r\n* Patients with enteric stomata or significant bowel resection\r\n* Prior history of corneal ulceration\r\n* Patients with any evidence of severe or uncontrolled systemic liver disease including those with known hepatitis B and hepatitis C (excluding treated hepatitis C that has been cured)\r\n* Active bleeding diatheses
Patients with a documented history of interstitial lung disease or pulmonary fibrosis
History of interstitial lung disease or pneumonitis
Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
Active interstitial lung disease; asthma requiring more than as needed bronchodilators for management; or other autoimmune lung disease
Has evidence of interstitial lung disease or active, non-infectious pneumonitis; has an active infection requiring systemic therapy
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Has any history of interstitial lung disease (pulmonary fibrosis or severe radiation pneumonitis) or is suspected to have such disease by imaging during screening
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).
Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
Has interstitial lung disease
History of extensive, disseminated, bilateral or presence of grade 3 or 4 interstitial fibrosis or interstitial lung disease including pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis; patients with history of prior radiation pneumonitis are not excluded
History of interstitial lung disease or pneumonitis
History of extensive disseminated/bilateral or known presence of interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.
History of interstitial lung disease (ILD).
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).
Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
Has history of interstitial lung disease.
Has active, or a history of, interstitial lung disease.
Have history of interstitial lung disease or pneumonitis.
Known interstitial lung disease.
History of interstitial lung disease (Parts D and E only).
Has clinical or radiologic evidence of interstitial lung disease or active, non-infectious pneumonitis
